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Abstract
 Background—Little is known about the impact of hospitalization for an acute myocardial 
infarction (AMI) on subsequent adherence to statins.
 Methods and Results—Using administrative claims from a 5% random sample of Medicare 
beneficiaries, we identified a cohort of Medicare patients ≥65 years, hospitalized from 2007–2011, 
taking statins in the year before AMI hospitalization (n=6,618). We then determined the 
proportion of patients nonadherent to statins (proportion of days covered [PDC] <80%) in the year 
before AMI hospitalization who became statin adherent (PDC ≥80%) in the year after AMI 
hospitalization. The proportion of statin adherent patients who became nonadherent was also 
studied. These proportions were compared with patients hospitalized for pneumonia (n=11,471) 
and patients not hospitalized (n=158,099) in 2010 and 2011. Among patients nonadherent to 
statins before AMI hospitalization, 37.7% became adherent after discharge. Patients hospitalized 
for AMI were more likely to become adherent than patients hospitalized for pneumonia (aRR 1.70, 
95%CI 1.57–1.84) or patients not hospitalized (aRR 1.79, 95%CI 1.68–1.90). Among patients 
adherent to statins before AMI hospitalization, 32.6% became nonadherent after discharge. Those 
hospitalized for AMI were less likely to become nonadherent than those hospitalized for 
pneumonia (aRR 0.93, 95%CI 0.88–0.98) but more likely to become nonadherent than patients 
without hospitalizations (aRR 1.41, 95%CI 1.35–1.48).
 Conclusions—Among nonadherent patients, hospitalization for AMI was associated with 
increased likelihood of becoming adherent to statins compared to hospitalization for pneumonia or 
Address for Correspondence: Ian M Kronish, MD, MPH, Columbia University Medical Center, 622 West 168th Street, PH9-311, New 
York, NY 10032, Tel: 212-342-1335, Fax: 212-342-3431, ik2293@columbia.edu. 
Conflict of Interest Disclosures: Dr. Ross receives research support through Yale University from Medtronic, Inc. and Johnson & 
Johnson to develop methods of clinical trial data sharing, from the Centers of Medicare and Medicaid Services (CMS) to develop and 
maintain performance measures that are used for public reporting, and from the Food and Drug Administration (FDA) to develop 
methods for post-market surveillance of medical devices. Dr. Muntner receives research support from Amgen Inc. None of the authors 
has financial relationships with industry.
HHS Public Access
Author manuscript
Circ Cardiovasc Qual Outcomes. Author manuscript; available in PMC 2017 July 01.
Published in final edited form as:













no hospitalizations. Among adherent patients, hospitalization for AMI was associated with 
increased likelihood of becoming nonadherent to statins compared to no hospitalizations.
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 Introduction
Hospitalization for a health event such as an acute myocardial infarction (AMI) has potential 
to either positively or negatively impact adherence to cardiovascular medications. 
Hospitalization for AMI may serve as a teachable moment that motivates patients to adopt 
positive cardiovascular health behaviors including adherence to medications in an effort to 
prevent further disease.(1–3) However, life-threatening health events may also induce 
depression, post-traumatic stress disorder, and other forms of psychological distress that are 
associated with poor adherence to recommended health behaviors.(4–8) Some patients may 
additionally experience a “post-hospital syndrome” in which they temporarily develop 
physical and cognitive disabilities as a consequence of the stressfulness of a hospitalization; 
this syndrome may impair patients’ ability to adhere to a medical regimen following 
discharge.(9) Challenges that arise during transitions in care from hospital to home may 
further impede adherence after hospitalization.(10)
Adherence to cardiovascular medications is one of the most important health behaviors after 
hospitalization for AMI.(11) Poor adherence to statins has been associated with increased 
risk for recurrent cardiovascular events and mortality, increased healthcare costs, and 
preventable readmissions.(12–15) Previous studies have documented substantial 
nonadherence to statins after hospitalization for AMI,(16–18) but few data have been 
published on changes in adherence to statins from before to after an AMI hospitalization.
(19) Determining the impact of an AMI hospitalization on adherence to statins after 
discharge can guide clinical expectations of statin adherence and can inform the design of 
interventions to improve adherence.
To increase the understanding of the impact of an AMI hospitalization on adherence to 
statins, we examined changes in adherence to statins from the year before to the year after 
hospitalization for an AMI. First, to determine whether changes in statin adherence from 
before to after hospitalization for AMI suggest an opportunity for a teachable moment, we 
compared changes in statin adherence experienced by those hospitalized for AMI with a 
control group of patients hospitalized for a non-cardiovascular problem unassociated with 
statin use, pneumonia. To ensure that changes in statin adherence after hospitalization for 
AMI were not due to regression to the mean, we compared patients hospitalized for AMI 
with a second control group of patients not hospitalized. Finally, to evaluate whether the 
experience of being hospitalized, in itself, results in worsening adherence, we compared 
changes in adherence among patients hospitalized for AMI, hospitalized for pneumonia, and 
patients not hospitalized.
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 Sources of Data
We obtained administrative claims on a 5% random sample of Medicare beneficiaries from 
the Centers for Medicare and Medicaid Services (CMS) Chronic Condition Data Warehouse. 
Medicare is a federal program that provides health insurance for adults ≥65 years in the 
United States. Insurance through Medicare is provided as a fee-for-service program or by 
contracts with healthcare organizations (Part C or Medicare Advantage). Data for the current 
analyses included claims from Medicare fee-for-service Parts A (inpatient), B (outpatient), 
and D (prescription drug). Medicare claims and assessment data from Parts A, B, and D are 
linked by beneficiary across the continuum of care. Beneficiaries with Part C coverage 
(Medicare managed care) were not included as their claims are not complete. Institutional 
review boards at the University of Alabama at Birmingham and CMS approved these 
analyses. Data for these analyses are stored at the University of Alabama at Birmingham.
 Patient Population
We identified three cohorts of patients (Supplemental Figure 1). Our main study population 
included Medicare beneficiaries who were hospitalized for AMI with an admission date on 
or after January 1, 2007 and a discharge date on or before December 31, 2011. Our first 
control population included beneficiaries who were hospitalized for pneumonia during this 
time period but not hospitalized for AMI from 365 days before the pneumonia 
hospitalization to 182 days after discharge. AMI was defined by International Classification 
of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) code 410.xx (except 410.x2 
which indicates a subsequent episode of care) in the primary discharge diagnosis position in 
Medicare inpatient files. Pneumonia was defined as a hospitalization with an overnight stay 
with an ICD-9 diagnosis of 480–488.11 in the primary discharge diagnosis position. For 
these cohorts, patients were required to be between 65 and 110 years at 365 days prior to the 
date of hospital admission and have at least one fill for a statin between the 182 and 365 
days prior to admission so that statin adherence in the year before hospitalization could be 
calculated over a minimum of 182 days. Additional eligibility criteria included having a 
duration of hospitalization less than 31 days; having Parts A, B, and D coverage for each 
month beginning 365 days before hospital admission through 182 days after discharge; 
living in the U.S.; being in the 5% Medicare sample; and not receiving hospice care during 
this period. The third cohort included Medicare beneficiaries who were not hospitalized in 
2010 and 2011. These patients had to be between 65 and 110 years on January 1, 2010; have 
at least one statin fill in the 182 to 365 days before January 1, 2011 (i.e., January 1, 2010 to 
June 30, 2010); have continuous Medicare Parts A, B, D but not C coverage; live in the U.S.; 
be in the 5% Medicare sample; and not receiving hospice services from January 1, 2010 
through June 30, 2011.
 Assessment of Statin Adherence
Statin prescription fills were identified in the Medicare Part D claims using National Drug 
Codes (NDCs). Statins included atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, 
and simvastatin. Adherence to statins was calculated using the interval-based proportion of 
days covered (PDC).(20,21) To calculate the PDC before the AMI hospitalization and, 
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separately, the pneumonia hospitalization, the denominator was the number of days from the 
first statin fill between 182 to 365 days before hospital admission until the date of hospital 
admission. The numerator was the total number of days during this period for which the 
patient had a statin available; if a prescription was filled earlier than the last day supplied by 
the previous fill, the overlapping supply was added to the end of the last prescription fill.7 
Patients were considered to have statins available regardless of brand, dose, or switching 
types of statins. Adherence after hospitalization was calculated from the date of discharge to 
365 days following discharge, date of death, date of loss of Parts A, B, and D coverage or 
initiation of Part C coverage using the PDC, and an identical approach was applied to the 
period before hospitalization. Days of supply at the time of hospital admission for the AMI 
were carried forward and applied to the calculation of PDC after discharge. For those not 
hospitalized, PDC was calculated from the first statin fill between January 1 and June 30, 
2010 through December 31, 2010 and, separately, between January 1, 2011 and December 
31, 2011. Patients were categorized a priori as nonadherent (PDC <80%) or adherent (PDC 
≥80%) for the time periods before and after AMI or pneumonia hospitalization or January 1, 
2011 for the no hospitalization cohort. The 80% cutpoint was used as this has been 
associated with increased mortality risk(14) and is the convention for studies of adherence to 
cardiovascular medications.(11,16,22)
 Patient Demographic and Clinical Characteristics
Demographic covariates, identified in the Medicare beneficiary summary file, included age, 
sex, race/ethnicity, urban versus rural residence based on metropolitan statistical area codes, 
receipt of a low-income subsidy in at least 1 month prior to AMI or pneumonia 
hospitalization or prior to January 1, 2011 for the not hospitalized cohort. Medicare claims 
and validated algorithms were used to identify the presence of comorbidities including 
coronary heart disease, diabetes, chronic kidney disease, depression, dementia, receipt of 
home care services, and total number of medication classes filled during the period before 
AMI or pneumonia hospitalization or before January 2011 for those in the not hospitalized 
cohort.(23–26) Coronary artery bypass graft surgery (CABG) during the AMI 
hospitalization was also assessed.
 Statistical Analysis
Characteristics for patients hospitalized for AMI were calculated by adherence status 
(adherent versus nonadherent) prior to their hospitalization. Cross-tabulation of adherence 
status before and after AMI hospitalization was also calculated. This enabled us to compare 
the percentages of patients who changed from nonadherent to adherent and from adherent to 
nonadherent in the year before to the year after AMI hospitalization. For comparison, cross-
tabulations of adherence status before and after pneumonia hospitalization and, separately, 
from 2010 to 2011 for patients not hospitalized, were also calculated. The AMI, pneumonia, 
and no hospitalization cohorts were also pooled to compare changes in adherence status 
between cohorts.
Among patients who were nonadherent before hospitalization or January 1, 2011 for those 
not hospitalized, we calculated the relative risk for becoming adherent after AMI 
hospitalization versus pneumonia hospitalization, AMI hospitalization versus no 
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hospitalization, and pneumonia hospitalization versus no hospitalization. Among patients 
who were adherent before hospitalization or January 1, 2011 for those not hospitalized, we 
calculated the relative risks for becoming nonadherent between the three groups. Relative 
risks were calculated using Poisson regression models with sandwich estimators and 
adjustment for age, sex, race, eligibility for low-income subsidy, urban residence, area level 
income, comorbidities (coronary heart disease, diabetes, chronic kidney disease, depression, 
dementia), number of medication classes, receipt of home health services, and in the 
nonadherent to adherent analyses only, PDC<50% versus 50%–79%. Poisson regression was 
used as it provides a direct estimate of the relative risk.(27–29)
To eliminate the influence of small changes in adherence near the 80% threshold when 
categorizing adherence, sensitivity analyses were conducted in which an improvement in 
adherence was defined as a change in PDC from <80% to ≥80% with a 10% or larger 
increase in PDC. Analogously, in sensitivity analyses, a decline in adherence was defined as 
a change in PDC from ≥80% to <80% with a 10% or larger decrease in PDC. Increases in 
PDC with cardiovascular medications after AMI of 4% to 6% have been associated with a 
reduction in rates of first vascular events, suggesting that the choice of a minimum change in 
statin adherence of at least 10% represents a clinically significant change.(30)
To quantify the change in mean PDC for statins between the periods before and after the 
AMI hospitalization, we conducted secondary analyses in which we calculated the change in 
the PDC between the two time periods as a continuous variable. We used linear regression to 
compare the change in adherence, modeled as a continuous variable, between the two time 
periods for the patients in the AMI hospitalization cohort versus patients in the pneumonia 
hospitalization cohort and patients not hospitalized. We conducted these analyses for 
patients who were nonadherent and, separately, those who were adherent in the first time 
period. All analyses were conducted using SAS 9.3 (SAS Institute, Research Triangle Park, 
NC).
 Results
Overall, 6,618 Medicare beneficiaries with an AMI hospitalization, 11,471 beneficiaries 
with a pneumonia hospitalization, and 158,099 beneficiaries without hospitalizations met the 
study eligibility criteria (Supplemental Figure 1). Compared to patients who were adherent 
to statins before AMI hospitalization, those who were nonadherent were more likely to be 
younger, non-white, live in low-income areas, and receive home health services (Table 1). 
Prior to AMI hospitalization, 36.4% of patients were nonadherent to statins. In comparison, 
31.6% of patients were nonadherent prior to pneumonia hospitalization and 28.3% of 
patients not hospitalized were nonadherent in 2010 (Supplemental Table 1). After AMI 
hospitalization, the proportion of patients who were nonadherent to statins increased to 
43.4%. In comparison, the proportion of patients who were nonadherent after pneumonia 
hospitalization increased to 48.9% and the proportion of patients who were nonadherent in 
2011 increased to 40.6%.
Kronish et al. Page 5













 Change from Nonadherent to Adherent
Among 2,408 patients who were nonadherent to statins before AMI hospitalization, 37.7% 
were adherent in the subsequent year. In comparison, 22.5% of those hospitalized for 
pneumonia and 20.6% of those not hospitalized became adherent (Figure 1). After 
multivariable adjustment, patients hospitalized for AMI were more likely to become 
adherent compared with patients hospitalized for pneumonia [adjusted relative risk (aRR) 
1.70, 95%CI, 1.57–1.84)] and those not hospitalized (aRR 1.79, 95% CI, 1.68–1.90). 
Patients hospitalized for pneumonia were not more likely to become adherent to statins than 
patients who were not hospitalized (aRR 1.00, 95%CI, 0.94–1.07). Results were similar in 
sensitivity analyses defining becoming adherent as a change in PDC from <80% to ≥80% 
with a 10% or larger increase in PDC (Supplemental Table 2).
Among patients who were nonadherent before their AMI hospitalization, eligibility for low-
income subsidy and living in higher-income areas were associated with greater likelihood of 
becoming adherent to statins after discharge (Table 2). The presence of pre-existent coronary 
heart disease, diabetes, and PDC<50% were associated with lower likelihood of becoming 
adherent after discharge.
In secondary analyses, among patients who were nonadherent before AMI hospitalization, 
mean PDC increased from 51% to 61% (Table 3). After multivariable adjustment, patients 
with an AMI hospitalization had 15.4% and 15.0% larger increases in mean PDC than their 
counterparts hospitalized for pneumonia and without a hospitalization, respectively (both 
p<0.001; Supplemental Table 3).
 Change from Adherent to Nonadherent
Among 4,210 patients who were adherent to statins before an AMI hospitalization, 32.6% 
became nonadherent after discharge. In comparison, 35.8% of patients hospitalized for 
pneumonia and 25.2% of those not hospitalized became nonadherent (Figure 2). After 
multivariable adjustment, those with an AMI hospitalization were less likely to become 
nonadherent than those with a pneumonia hospitalization (aRR 0.93, 95% CI, 0.88–0.98). 
Those with an AMI hospitalization (aRR 1.41, 95% CI, 1.35–1.48) and, separately, those 
with a pneumonia hospitalization (aRR 1.57, 95%CI, 1.52–1.63) were more likely than those 
not hospitalized to become nonadherent. Results were similar in sensitivity analyses defining 
becoming nonadherent as a change in PDC from ≥80% to <80% with a 10% or larger 
decrease in PDC (Supplemental Table 4).
Among those who were adherent before their AMI hospitalization, older age, diabetes, 
depression, and dementia were associated with increased risk of becoming nonadherent after 
hospital discharge whereas eligibility for low-income subsidy was associated with decreased 
risk of becoming nonadherent (Table 4).
In secondary analyses that examined the change in mean adherence among patients with a 
PDC ≥80% before AMI hospitalization, mean PDC adherence declined from 94% to 81% 
(Table 3). After multivariable adjustment, patients with an AMI hospitalization had a 2.7% 
smaller decline in mean PDC adherence compared with patients with a pneumonia 
hospitalization (p<0.001; Supplemental Table 3). Compared to patients without 
Kronish et al. Page 6













hospitalizations, patients with an AMI hospitalization and a pneumonia hospitalization had 
3.4% and 6.6% larger declines in mean PDC, respectively, after multivariable adjustment 
(both p<0.001).
 Conclusions
In the current study of statin adherence before and after hospitalization for AMI, more than 
40% of Medicare beneficiaries were nonadherent to statins after AMI, and the overall 
proportion of beneficiaries that was nonadherent increased from before to after the AMI 
hospitalization. Despite this overall worsening in adherence after AMI hospitalization, 
patients who were nonadherent to statins before hospitalization for AMI were nearly two 
times more likely to become adherent after discharge as compared to patients hospitalized 
for pneumonia or those not hospitalized. This finding supports the hypothesis that a 
hospitalization for AMI can act as teachable moment that promotes adherence to treatments 
prescribed to prevent recurrent events. In contrast, patients who were adherent to statins 
before hospitalization for AMI or pneumonia were more likely to become nonadherent after 
discharge compared to patients with no hospitalizations. This suggests that a hospitalization, 
irrespective of the reason, can also have an adverse impact on medication adherence.
The conceptual model underlying teachable moments is that health events transiently 
increase perceived vulnerability to the disease underlying the health event and trigger a 
reassessment of the expected risks and benefits of relevant health behaviors.(31,32) These 
processes, in turn, may promote a tipping point toward positive health behavior change. 
While several studies have shown that health events, such as cancer diagnosis, pregnancy, or 
AMI, can increase smoking cessation,(2,33) there are few data showing that health events 
can positively influence medication adherence.(19) Several small studies show that 
clinicians can enhance the effect of the teachable moment by drawing clear connections 
between the health event and preventive health behaviors when counseling patients.(34,35) 
Thus, our study implies that clinicians can promote statin adherence after AMI by explicitly 
linking the prevention of recurrent cardiac events to medication adherence.
Hospitalization for either AMI or pneumonia was associated with a modest worsening in 
adherence to statins in patients who were adherent before hospitalization. The inclusion of a 
control group of patients with no hospitalizations enabled us to ensure that this worsening in 
adherence was not simply due to regression to the mean. Patients who were older and those 
with comorbid depression or dementia represented vulnerable subgroups who were at 
significantly higher risk of a decline in adherence after hospital discharge. These findings 
are consistent with evidence showing that disjointed transitions in care from hospital to 
home can produce medication reconciliation errors that put patients, especially those from 
vulnerable groups, at risk for medication nonadherence.(36,37) These findings also support 
the post-hospital syndrome hypothesis that the hospitalization, in itself, impairs patients’ 
ability to adhere to medications after discharge. To prevent a decline in adherence after 
hospitalization, there is a need for increased attention to interventions that take place 
immediately after discharge to help optimize adherence after hospitalization as opposed to 
solely focusing on the in-hospital discharge process.(38) Furthermore, interventions that 
reduce the stress of hospitalization by optimizing sleep and keeping patients mentally and 
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physically active during their stay may have a beneficial effect on medication adherence 
after discharge.(39)
There are a number of strengths to the current study. Medicare claims include data for a 
large national sample that is highly generalizable to older US adults. Medicare claims also 
capture continuity of care for patients, thus allowing us to examine adherence before and 
after hospitalization. Additionally, using Medicare claims facilitates the evaluation of a 
number of factors that may influence adherence, including demographics, comorbidities, and 
polypharmacy. Despite these strengths, the current study should be interpreted in the context 
of certain limitations. Although we required patients to have continuous Medicare Part D 
coverage, some may have paid for their statins without a Part D claim being submitted.(40) 
Additionally, patients hospitalized for AMI may have disproportionately received free 
samples of statins after discharge. Further, some patients may have been advised by their 
physician to discontinue their statin during the study period, and Medicare claims do not 
capture this information. These unmeasured factors may have led to the misclassification of 
adherent patients as nonadherent, and may have led to an overestimate of the adverse impact 
of hospitalization on nonadherence. Also, the analysis was limited to fee-for-service 
Medicare beneficiaries, and it is unknown whether the findings extend to younger patients or 
patients enrolled in a Medicare Advantage program. Finally, the analysis was limited to 
patients who survived until at least six months after the initial hospitalization, which may 
have biased the sample toward being more adherent.
In conclusion, a substantial proportion of patients will have an improvement in adherence to 
statins after AMI hospitalization. Even with this improvement, approximately 40% of 
patients are likely to be nonadherent after AMI. Efforts to improve adherence to statins after 
AMI have met with disappointing results in prior studies.(41,42) The results of the current 
study suggest that an AMI may present a potent opportunity for motivating patients to 
become adherent to cardiovascular medications, and counseling interventions that emphasize 
the connection between statin adherence and recurrent AMI prevention may be particularly 
effective. Also, a hospitalization, regardless of the cause, appears to represent a vulnerable 
period that is associated with a worsening in adherence in a substantial proportion of 
patients. Quality improvement initiatives that incorporate adherence monitoring after 
discharge are needed to prevent a decline in adherence after AMI hospitalization.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Nonadherence to statins is common after hospitalization for acute 
myocardial infarction (AMI).
• Patients who are nonadherent to statins after AMI are at increased risk 
for recurrent cardiovascular events and have higher healthcare costs.
What the Study Adds
• Medicare beneficiaries who are hospitalized for an AMI are nearly 
twice as likely to become adherent to statins as compared to 
beneficiaries hospitalized for a non-cardiac reason.
• A hospitalization for an AMI may represent a teachable moment that 
can be leveraged to motivate patients to improve their adherence to 
statins.
• A hospitalization for an AMI also represents a vulnerable period that 
can lead to a worsening in statin adherence in about 1 in 3 Medicare 
beneficiaries.
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Proportion of Nonadherent Patients That Become Adherent to Statins after Acute 
Myocardial Infarction Hospitalization, Pneumonia Hospitalization, or in 2011 versus 2010 
for those without a Hospitalization. Patients were considered adherent if proportion of days 
covered (PDC) with statins was ≥80% and nonadherent if PDC<80%.
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Proportion of Adherent Patients That Become Nonadherent After Acute Myocardial 
Infarction Hospitalization, Pneumonia Hospitalization, or in 2011 versus 2010 for those 
without a Hospitalization. Patients were considered adherent if proportion of days covered 
(PDC) with statins was ≥80% and nonadherent if PDC<80%.
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Table 1
Sociodemographic and Clinical Characteristics According to Level of Statin Adherence in the Year Before 
Hospitalization for Acute Myocardial Infarction (N=6,618).
Adherence before AMI hospitalization
Characteristic Nonadherent; PDC<80% (N=2,408; 36.4%) Adherent; PDC ≥80% (N=4,210; 63.6%)
Age, in years
 65–69 458 (19.0) 709 (16.8)
 70–74 584 (24.3) 904 (21.5)
 75–79 532 (22.1) 915 (21.7)
 80–84 445 (18.5) 810 (19.2)
 85–110 389 (16.2) 872 (20.7)
Female gender 1,378 (57.2) 2,324 (55.2)
Non-white race/ethnicity 455 (18.9) 510 (12.1)
Eligible for low-income subsidy 1,048 (43.5) 1,803 (42.8)
Urban residence 1,587 (66.8) 2,821 (68.2)
Area-level income, $
 <30,000 648 (27.3) 1,011 (24.5)
 30,000-<75,000 1,581 (66.6) 2,812 (68.2)
 75,000+ 145 (6.1) 303 (7.3)
Comorbidity
 Coronary heart disease 1,545 (64.2) 2,739 (65.1)
 Diabetes mellitus 1,147 (47.6) 2,031 (48.2)
 Chronic kidney disease 572 (23.8) 954 (22.7)
 Depression 318 (13.2) 504 (12.0)
 Dementia 253 (10.5) 415 (9.9)
Receive home health services 514 (21.3) 805 (19.1)
Number of medication classes
 <5 139 (5.8) 205 (4.9)
 5 – 9 658 (27.3) 1,134 (26.9)
 ≥10 1,611 (66.9) 2,871 (68.2)
AMI – Acute myocardial infarction, PDC – proportion of days covered.
Numbers in table are sample size (column percentage)
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Table 2
Sociodemographic and Clinical Characteristics Associated with Changing from Nonadherent to Statins before 






 65–74 1 (ref) 1 (ref)
 75–84 1.07 (0.96 , 1.20 ) 1.07 (0.96 , 1.20 )
 85+ 0.97 (0.83 , 1.13 ) 0.96 (0.82 , 1.13 )
Female gender 1.00 (0.90 , 1.11 ) 1.01 (0.90 , 1.12 )
Non-white race/ethnicity 0.85 (0.74 , 0.98 ) 0.86 (0.73 , 1.01 )
Eligible for low-income subsidy 0.99 (0.89 , 1.10 ) 1.13 (1.01 , 1.27 )
Urban residence 1.00 (0.90 , 1.12 ) 1.01 (0.90 , 1.13 )
Area-level income, $
 <30,000 1 (ref) 1 (ref)
 30,000-<75,000 1.13 (1.00 , 1.28 ) 1.09 (0.96 , 1.24 )
 75,000+ 1.25 (1.00 , 1.55 ) 1.26 (1.00 , 1.59 )
Comorbidity
 Coronary heart disease 0.79 (0.72 , 0.88 ) 0.81 (0.73 , 0.91 )
 Diabetes mellitus 0.82 (0.74 , 0.91 ) 0.87 (0.78 , 0.97 )
 Chronic kidney disease 0.86 (0.76 , 0.98 ) 0.91 (0.79 , 1.05 )
 Depression 0.88 (0.75 , 1.04 ) 0.89 (0.75 , 1.06 )
 Dementia 0.86 (0.71 , 1.03 ) 0.85 (0.70 , 1.03 )
Number of medication classes before MI
 <5 1 (ref) 1 (ref)
 5 – 9 0.83 (0.68 , 1.01 ) 0.88 (0.72 , 1.08 )
 ≥10 0.75 (0.62 , 0.90 ) 0.85 (0.69 , 1.04 )
Before hospitalization PDC<50% 0.72 (0.64 , 0.80 ) 0.71 (0.63 , 0.79 )
CABG during hospitalization 1.14 (0.96 , 1.35 ) 1.02 (0.86 , 1.21 )
Receive home health services 0.99 (0.87 , 1.12 ) 1.14 (0.99 , 1.30 )
Abbreviations: RR, relative risk; AMI, acute myocardial infarction; PDC, proportion of days covered; CABG, coronary artery bypass graft surgery
*
Analyses were conducted using the primary definition of adherence in which patients were categorized as adherent if PDC ≥80%.
†
Adjusted analyses include all the variables listed in the table.
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Table 3
Change in Mean Adherence to Statins from Before to After Acute Myocardial Infarction Hospitalization, 
Pneumonia Hospitalization, and No Hospitalization in Patients Who Were Nonadherent in the First Time 
Period, and in Patients Who Were Adherent in the First Time Period*
Nonadherent to Statins (PDC <80%) in First Time Period




51.1% (21.0%) 52% (21%) 53.3% (20.0%)
Post-hospitalization adherence, 
mean PDC (SD)
61.1% (32.1%) 45.6% (34.7%) 48.0% (31.9%)
Change in adherence, [post 
minus pre- hospitalization PDC 
(95%CI)]†
10.0% (8.8%, 11.1%) −6.0% (−6.9%, −5%) −5.3% (−5.5%, −5.1%)
Adherent to Statins (PDC ≥80%) in First Time Period




94.4% (5.5%) 94.6% (5.5%) 95.0% (5.3% )
Post-hospitalization adherence, 
mean PDC (SD)
80.6% (22.2%) 77.7% (24.7%) 84.1% (17.4%)
Change in adherence [post 
minus pre- hospitalization PDC 
(95%CI)]‡
−13.8% (−14.3%, − 13.2%) −16.9% (−17.4%, − 16.5%) −11.0% (−11.1%, − 10.9%)
Abbreviations: AMI, acute myocardial infarction; PDC, proportion of days covered
*
Proportion of days covered with statins is presented as a continuous measure in this table. The first time period refers to the one year period before 
the first hospitalization for AMI or pneumonia among patients with this type of hospitalization between 2007 and 2011 or to the one year period 
spanning 2010 for patients with no hospitalizations in 2010 and 2011.
†
P-interaction <0.001 comparing all three groups. P-interaction <0.001 for the pairwise comparison of pneumonia hospitalization with AMI 
hospitalization, and no hospitalization with AMI hospitalization. P-interaction=0.11 for the pairwise comparison of no hospitalization with 
pneumonia hospitalization.
‡
P-interaction <0.001 comparing all three groups. P-interaction <0.001 for the pairwise comparison of pneumonia hospitalization with AMI 
hospitalization, no hospitalization with AMI hospitalization and no hospitalization with pneumonia hospitalization.
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Table 4
Sociodemographic and Clinical Characteristics Associated with Changing from Adherent before 






 65–74 1 (ref) 1 (ref)
 75–84 1.17 (1.05 , 1.29 ) 1.13 (1.02 , 1.25 )
 85+ 1.31 (1.17 , 1.47 ) 1.26 (1.11 , 1.43 )
Female gender 1.07 (0.98 , 1.17 ) 1.01 (0.92 , 1.11 )
Non-white race/ethnicity 1.06 (0.93 , 1.21 ) 1.05 (0.91 , 1.21 )
Eligible for low-income subsidy 0.96 (0.88 , 1.05 ) 0.88 (0.80 , 0.98 )
Urban residence 0.94 (0.85 , 1.03 ) 0.98 (0.88 , 1.08 )
Area-level income, $
 <30,000 1 (ref) 1 (ref)
 30,000–<75,000 1.09 (0.98 , 1.21 ) 1.07 (0.96 , 1.20 )
 75,000+ 1.1 (0.91 , 1.32 ) 1.07 (0.88 , 1.29 )
Comorbidity
 Coronary heart disease 1.03 (0.94 , 1.13 ) 1.01 (0.91 , 1.11 )
 Diabetes mellitus 1.12 (1.02 , 1.22 ) 1.10 (1.00 , 1.21 )
 Chronic kidney disease 1.18 (1.07 , 1.30 ) 1.09 (0.98 , 1.21 )
 Depression 1.25 (1.11 , 1.41 ) 1.15 (1.01 , 1.31 )
 Dementia 1.37 (1.22 , 1.55 ) 1.23 (1.08 , 1.40 )
Number of medication classes before AMI
 <5 1 (ref) 1 (ref)
 5 – 9 1.01 (0.80 , 1.28 ) 0.96 (0.75 , 1.21 )
  ≥10 1.22 (0.97 , 1.52 ) 1.06 (0.84 , 1.35 )
CABG during hospitalization 0.93 (0.79 , 1.09 ) 1.03 (0.87 , 1.22 )
Receive home health services 1.22 (1.11 , 1.35 ) 1.10 (0.99 , 1.23 )
Abbreviations: RR, relative risk; CI, confidence interval; AMI, acute myocardial infarction; CABG, coronary artery bypass graft surgery
*
Analyses were conducted using the primary definition of adherence in which patients were categorized as adherent if PDC ≥ 80%.
†
Adjusted analyses include all the variables listed in the table.
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